Youth diagnosed with type 2 diabetes may require a combination treatment or insulin therapy within a few years after diagnosis, according to a study published online April 29 in the New England Journal of Medicine.
Youth diagnosed with type 2 diabetes may require a combination treatment or insulin therapy within a few years after diagnosis, according to a study published online April 29 in the New England Journal of Medicine.
The results are from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study led by Philip Zeitler, MD, PhD, section head of endocrinology at Children's Hospital Colorado in Aurora and professor of pediatrics and clinical sciences at the University of Colorado School of Medicine in Denver.
Dr Zeitler and colleagues noted that there are few data to guide treatment despite the rising rate of youth diagnosed with type 2 diabetes. They designed the multicenter, randomized clinical trial to test the hypothesis that combination therapy initiated early would maintain acceptable glycemic control better than metformin alone.
The investigators randomly assigned 699 (75.4%) patients, aged 10 to 17 years, to receive metformin (at a dose of 1,000 mg twice daily) alone, metformin plus rosiglitazone (4 mg twice daily), or metformin plus a lifestyle-intervention program, which focused on weight loss through family-based changes in eating and behavior. Patients were followed for an average of 3.86 years for a primary outcome of loss of glycemic control.
Of the 699 participants, 319 (45.6%) reached the primary outcome, with a median time to treatment failure of 11.5 months. The investigators noted that 51.7% of patients treated with metformin monotherapy had treatment failure-a rate higher than that observed in recently diagnosed adult patients. In addition, they noted that metformin combined with lifestyle intervention was no better than metformin alone in maintaining glycemic control with 46.6% of patients experiencing treatment failure. The combination of metformin and rosiglitazone improved the durability of glycemic control, but 38.6% still had treatment failure.
“Further analysis is required to determine whether the apparent decrease in the durability of glycemic control with metformin in adolescents as compared with adults reflects biologic differences, pathophysiological differences, or both,” the authors wrote. “Further analysis of the effect of various components of the lifestyle intervention is needed to understand the current findings and identify ways to effectively integrate behavioral self-management in the ongoing care of youth with type 2 diabetes,” they added.
In an editorial that accompanied the study, David B. Allen, MD, from the Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, noted that the issue is a societal and cultural problem that needs to be resolved through public policy, not medication.
“A critical point is that the participants in the TODAY study were not adults, but youth immersed from a young age in a sedentary, calorie-laden environment that may well have induced and now aggravates their type 2 diabetes. Fifty years ago, children did not avoid obesity by making healthy choices; they simply lived in an environment that provided fewer calories and included more physical activity for all. Until a healthier “eat less, move more” environment is created for today's children, lifestyle interventions like that in the TODAY study will fail,” Dr Allen wrote.
The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.